MLICM
NTLA icon

Metropolitan Life Insurance Company (MetLife)’s Intellia Therapeutics NTLA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,830
Closed -$133K – 1411
2024
Q1 		$133K Sell
4,830
-251
-5% -$6.97K 0.01% 903
2023
Q4 		$155K Hold
5,081
– – 0.01% 862
2023
Q3 		$161K Buy
5,081
+263
+5% +$10.2K 0.01% 779
2023
Q2 		$196K Buy
4,818
+344
+8% +$13.9K 0.01% 687
2023
Q1 		$167K Sell
4,474
-777
-15% -$30.5K 0.01% 738
2022
Q4 		$183K Buy
5,251
+703
+15% +$33.4K 0.01% 753
2022
Q3 		$255K Hold
4,548
– – 0.01% 597
2022
Q2 		$235K Buy
4,548
+176
+4% +$8.94K 0.01% 641
2022
Q1 		$318K Sell
4,372
-13,338
-75% -$1.13M 0.01% 628
2021
Q4 		$2.09M Sell
17,710
-377
-2% -$47.2K 0.03% 504
2021
Q3 		$2.43M Buy
18,087
+643
+4% +$97.4K 0.04% 418
2021
Q2 		$2.82M Buy
17,444
+2,700
+18% +$210K 0.04% 373
2021
Q1 		$1.18M Buy
14,744
+739
+5% +$49.6K 0.02% 831
2020
Q4 		$762K Buy
14,005
+234
+2% +$8.5K 0.01% 1076
2020
Q3 		$274K Hold
13,771
– – ﹤0.01% 1596
2020
Q2 		$289K Buy
13,771
+1,634
+13% +$27.8K 0.01% 1572
2020
Q1 		$148K Sell
12,137
-2,305
-16% -$31.1K ﹤0.01% 1775
2019
Q4 		$212K Sell
14,442
-1,248
-8% -$17.4K ﹤0.01% 1883
2019
Q3 		$209K Buy
15,690
+4,574
+41% +$72.9K ﹤0.01% 1845
2019
Q2 		$182K Hold
11,116
– – ﹤0.01% 1948
2019
Q1 		$190K Hold
11,116
– – ﹤0.01% 1930
2018
Q4 		$152K Hold
11,116
– – ﹤0.01% 1999
2018
Q3 		$318K Hold
11,116
– – 0.01% 1687
2018
Q2 		$304K Buy
11,116
+5,464
+97% +$132K ﹤0.01% 1650
2018
Q1 		$119K Hold
5,652
– – ﹤0.01% 2200
2017
Q4 		$109K Sell
5,652
-5,364
-49% -$124K ﹤0.01% 2259
2017
Q3 		$274K Hold
11,016
– – ﹤0.01% 2085
2017
Q2 		$176K Buy
+11,016
New +$154K ﹤0.01% 2413
2016
Q3 		– Sell
-8,886
Closed -$190K – 2648
2016
Q2 		$190K Buy
+8,886
New +$236K ﹤0.01% 2350

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s NTLA Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Intellia Therapeutics (NTLA) in Q2 2024, closing a stake of 4,830 shares — an estimated $133K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in NTLA in Q2 2016 and held it in 29 quarters. The position peaked at $2.82M in Q2 2021. 291 funds tracked by Wall St. Rank hold NTLA as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Intellia Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 4,830 Intellia Therapeutics shares in Q2 2024, an estimated $133K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Intellia Therapeutics in Q2 2016 and held it in 29 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Intellia Therapeutics position peaked at $2.82M in Q2 2021.
  • 291 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.